<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232023</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0103</org_study_id>
    <nct_id>NCT01232023</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent</brief_title>
  <official_title>Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the pharmacokinetic and pharmacodynamic characteristics of
      indobufen in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24 Hours</time_frame>
    <description>AUC, Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>24 Hours</time_frame>
    <description>Platelet Aggregation Test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wild type UGT1A : 3 / Variant type UGT1A : 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wild type UGT1A : 3 / Variant type UGT1A : 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wild type UGT1A : 3 / Variant type UGT1A : 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wild type UGT1A : 3 / Variant type UGT1A : 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indobufen</intervention_name>
    <description>Single Oral Dose of</description>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_label>200mg</arm_group_label>
    <arm_group_label>400mg</arm_group_label>
    <arm_group_label>800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 19 to 50 years at screening.

          -  Subjects with body weight ≥ 45 kg and within ±20% of the ideal body weight : Ideal
             body weight = (height [cm] - 100)x0.9.

          -  Subjects who have received and understood completely the information regarding the
             current study and given written informed consents to voluntarily participate in the
             study and followed all instructions specified in the protocol.

        Exclusion Criteria:

          -  Subjects who have drunken habitually (exceeding 21 units/week, 1 unit = 10 g of pure
             alcohol) or who are unable to abstain from drinking during the study period from 2
             days prior to the first administration of investigational product and during this
             study.

          -  Subjects deemed ineligible by investigator based on other reasons, including abnormal
             laboratory values or diseases.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Seok Lim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangmin Choe, M.D., Ph.D.</last_name>
      <phone>82-55-360-1732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeong-Seok Lim, M.D., Ph.D.</last_name>
      <phone>82-2-3010-4613</phone>
    </contact>
    <investigator>
      <last_name>Hyeong-Seok Lim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://crc.amc.seoul.kr</url>
    <description>Clinical Research Center, Asan Medical Center</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Asan Medical Center, Clinical Pharmacology &amp; Therapeutics</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>Indobufen</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Indobufen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

